Supernus Pharmaceuticals | SUPN - Operating Profit


Supernus Pharmaceuticals reported $-60.18M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Abbott USD 2.25B 73M Dec/2025
ANI Pharmaceuticals USD 22.83M 7.66M Sep/2025
Aurora Cannabis CAD -55.67M 35.45M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Supernus Pharmaceuticals USD -60.18M 72.32M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Xeris Pharmaceuticals USD 6.73M 2.25M Sep/2025